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A novel mGluR5 antagonist, MFZ 10-7, inhibits
cocaine-taking and cocaine-seeking behavior in rats
Thomas M. Keck1, Mu-Fa Zou1, Guo-Hua Bi2, Hai-Ying Zhang2, Xiao-Fei Wang2, Hong-Ju Yang2,
Ratika Srivastava2, Eliot L. Gardner2, Zheng-Xiong Xi2 & Amy Hauck Newman1
Medicinal Chemistry Section, Molecular Targets and Medications Discovery Branch1 and Neuropsychopharmacology Section, Chemical Biology Research Branch,
Intramural Research Program2, National Institute on Drug Abuse, NIH, DHHS, Baltimore, MD, USA
ABSTRACT
Pre-clinical studies suggest that negative allostericmodulators (NAMs) of themetabotropic glutamate receptor subtype
5 (mGluR5), including 2-methyl-6-(phenylethynyl)pyridine (MPEP), 3-[(2-methyl-1,3-thiazol-4-yl)ethynyl]pyridine
(MTEP) and fenobam are highly effective in attenuating drug-taking and drug-seeking behaviors. However, bothMPEP
andMTEPhave no translational potential for use in humans because of their off-target effects and short half-lives. Here,
we report that 3-fluoro-5-[(6-methylpyridin-2-yl)ethynyl]benzonitrile (MFZ 10-7), a novel mGluR5 NAM, is more
potent and selective than MPEP, MTEP and fenobam in both in vitro binding and functional assays. Similar to MTEP,
intraperitoneal administration of MFZ 10-7 inhibited intravenous cocaine self-administration, cocaine-induced rein-
statement of drug-seeking behavior and cocaine-associated cue-induced cocaine-seeking behavior in rats. Although
MFZ 10-7 and MTEP lowered the rate of oral sucrose self-administration, they did not alter total sucrose intake.
Further, MFZ 10-7 appeared to be more potent than MTEP in inducing downward shifts in the cocaine dose–response
curve, but less effective than MTEP in attenuating sucrose-induced reinstatement of sucrose-seeking behavior. MFZ
10-7 and MTEP had no effect on basal locomotor behavior. These findings not only provide additional evidence
supporting an important role for mGluR5 in cocaine reward and addiction, but also introduce a new tool for both
in vitro and in vivo investigations with which to further characterize this role.
Keywords Cocaine, cue-induced cocaine seeking, MFZ 10-7, mGluR5, MTEP, reinstatement, self-administration,
sucrose.
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INTRODUCTION
Glutamate neurotransmission is critically involved in
drug reward and addiction (Olive et al. 2012). Glutamate
signaling occurs via functional activation of ionotropic
glutamate receptors and metabotropic glutamate recep-
tors (mGluRs). Eight mGluRs are classified into three
groups based on sequence homology and G protein inter-
actions: group I (mGluR1, mGluR5), group II (mGluR2,
mGluR3) and group III (mGluR4, mGluR6, mGluR7 and
mGluR8; Ferraguti & Shigemoto 2006). Activation of
mGluR1 and mGluR5, which are Gq protein-coupled,
induces mobilization of intracellular Ca2+ stores and
activation of phospholipase C (Schoepp & Conn 1993).
mGluR5 is expressed in multiple brain regions, including
the mesolimbic structures such as the ventral tegmental
area and the nucleus accumbens, that are critically
involved in drug reward and addiction (Shigemoto et al.
1993; Romano, Pol & O’Malley 1996). mGluR5 is mostly
located postsynaptically (Mitrano & Smith 2007) and
co-localized with dopamine D2, adenosine A2A and
N-methyl-D-aspartate (NMDA) receptors (Tebano et al.
2005).
mGluR5 became a major target of interest in medica-
tion development for treatment of addiction when it
was reported that mice lacking mGluR5 do not self-
administer cocaine and that blockade of mGluR5 by
2-methyl-6-(phenylethynyl)pyridine (MPEP), a negative
allosteric modulator (NAM), inhibits cocaine self-
administration (Chiamulera et al. 2001). Since then, a
series of investigations have reported that MPEP and
its analog 3-[(2-methyl-1,3-thiazol-4-yl)ethynyl]pyridine
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(MTEP), as well as fenobam significantly inhibit
behaviors associated with addiction in experimental
animals, including cocaine self-administration (Tessari
et al. 2004; Kenny et al. 2005; Lee et al. 2005; Paterson &
Markou 2005; Martin-Fardon et al. 2009; Keck et al.
2013), cocaine-induced conditioned place preference
(McGeehan & Olive 2003; Herzig & Schmidt 2004),
cocaine-induced hyperactivity (McGeehan, Janak & Olive
2004), and cocaine-, cue- or stress-induced reinstate-
ment of drug-seeking behavior (Lee et al. 2005;
Backström & Hyytiä 2006; Kumaresan et al. 2009;
Martin-Fardon & Weiss 2012; Keck et al. 2013; Wang
et al. 2013). These data strongly suggest that mGluR5
plays an important role in cocaine abuse and addiction
and that mGluR5 NAMsmay have potential for the treat-
ment of cocaine addiction in humans (Heidbreder et al.
2003; Olive et al. 2005).
However, MPEP and MTEP have not been tested in
human trials for multiple reasons (Lindsley & Emmitte
2009). Off-target effects of MPEP include positive
allostericmodulation of mGluR4 (Mathiesen et al. 2003),
antagonism of NMDA receptors (O’Leary et al. 2000;
Movsesyan et al. 2001), binding to the norepinephrine
transporter (Heidbreder et al. 2003) and inhibition of
monoamine oxidase A (Lea & Faden 2006). Although
MTEP is more selective than MPEP for mGluR5 (Cosford
et al. 2003; Lea & Faden 2006), it has been reported to
inhibit cytochrome P450 1A2 (Green, Jiang & King
2004), produce social isolation in rats (Koros et al. 2007)
and has reduced binding affinity for mGluR5 compared
with MPEP (Keck et al. 2012). These off-target effects
predict potential undesirable side effects or metabolic
instability that were deemed too risky to advance these
drugs into the clinic. In light of these limitations, exten-
sive efforts have been undertaken to develop novel potent,
selective and metabolically more stable mGluR5 NAMs
for potential translation to clinical investigation (Emmitte
2011; Nicoletti et al. 2011; Rocher et al. 2011).
3-Fluoro-5-[(6-methylpyridin-2-yl)ethynyl]benzo-
nitrile (MFZ 10-7) is a highly potent mGluR5 NAM (Keck
et al. 2012). Structurally, MFZ 10-7 is an analog of MPEP,
but has much higher mGluR5 binding affinity and
mGluR5 antagonist potency in vitro than MPEP, MTEP or
fenobam (Keck et al. 2012, 2013). In the present study,
we evaluated MFZ 10-7 in a broad receptor screen to
determine potential off-target effects, comparing its phar-
macological profile with MTEP as well as the clinically
investigated mGluR5 NAM fenobam. We then investi-
gated and compared the effects of MFZ 10-7 andMTEP on
cocaine self-administration maintained by a single dose
or multiple doses, cocaine priming-induced reinstate-
ment of drug-seeking behavior, and cocaine-associated
cue-induced cocaine-seeking behavior in rats—three
commonly used animal models to predict drug reward
and relapse (O’Brien & Gardner 2005). In addition, we
compared the effects of MFZ 10-7 and MTEP on oral
sucrose self-administration and reinstatement of sucrose
seeking behavior to determine whether both these
mGluR5 NAMs selectively inhibit cocaine-taking and
cocaine-seeking behavior versus sucrose-taking and
sucrose-seeking behavior. Finally, we observed the effects
of both compounds on open-field locomotor activity to
determine whether either compound produced non-
specific locomotor impairment that might underlie the
inhibitory effects on cocaine- or sucrose-taking or
-seeking behavior.
MATERIALS AND METHODS
Experiment 1: In vitro functional assay of
mGluR5 NAMs
To compare the in vitro potency (IC50) of MFZ 10-7,MPEP,
MTEP and fenobam under the same experimental con-
ditions, we used HEK293 cells stably expressing rat
mGluR5 in a competitive immunoassay to evaluate Gq
protein-mediated production of the intracellular messen-
ger inositol 1,4,5-trisphosphate (IP3; detailed immu-
noassay methods in Keck et al. 2012; stable construct
described in Romano et al. 1995). Briefly, the IP-One
enzyme-linked immunosorbent assay (Cisbio US, Bedford,
MA, USA) measures the accumulation of d-myo-inositol
1 phosphate (IP1), a degradation product of IP3, via
an anti-IP1 monoclonal antibody (Anti-IP1 Mab) and
IP1-horse-radish peroxidase (IP1-HRP) conjugate in the
presence of LiCl. For each assay, test compounds were
dissolved in 30% dimethyl sulfoxide (DMSO) and water to
a concentration of 100 μM and serially diluted in 1X
stimulation buffer; final test concentrations ranged
from 10 μM to 10 pM. After 1-hour incubation with test
compounds at 37°C, cells were lysed and the lysate was
treated with Anti-IP1 Mab and IP1-HRP. The optical
density (OD) of each treatment was determined at wave-
lengths of 450 nm and 620 nm (Spectramax M5 reader
and Softmax Pro 5.3 software, Molecular Devices,
Sunnyvale, CA, USA). IP1 levels for each treatment were
determined by subtracting the OD at 620 nm from the
OD at 450 nm and normalizing to vehicle-only control
values. IC50 values for inverse agonism (no agonist
present) were calculated from at least three independent
experiments.
Experiment 2: In vitro binding assays of mGluR5 NAMs
Receptor binding data forMPEP,MTEP and fenobamhave
been reported previously (Gasparini et al. 1999; Porter
et al. 2005), but the present experiment was designed
to compare the mGluR5 binding affinity (Ki) of these
compounds with MFZ 10-7 under identical experimental
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conditions, using experimental procedures reported pre-
viously (detailed methods in Keck et al. 2012). Briefly,
binding was performed in membranes prepared from the
brains of male Sprague−Dawley rats.Whole brainsminus
the cerebellum were homogenized in cold assay buffer
(50 mM Tris, 120 mM NaCl, 5 mM KCl, pH 7.4 at 25°C)
and centrifuged at 50 000 g for 10 minutes at 4°C. The
resulting pellet was re-suspended in cold assay buffer,
re-centrifuged and re-suspended in buffer to a concentra-
tion of 75 mg/ml. Ligand binding experiments were con-
ducted at room temperature for 60minutes in glass assay
tubes containing 0.5 ml total volume. Each reaction con-
tained 4 nM [3H]MPEP (American Radiolabeled Chemi-
cals, St. Louis, MO, USA), 7.5 mg of brain tissue (original
wet weight), and varying concentrations of test com-
pounds. Non-specific binding was determined using
100 μM MPEP. Incubations were terminated by rapid fil-
tration and washing with cold assay buffer. Filters were
transferred to scintillation vials, scintillation fluid was
added and the vials were counted in a liquid scintillation
counter. Each compound was tested over full dose–
response curves, with test compound concentrations at
half-log units ranging from 10 pM to 100 μM final con-
centration, performed in triplicate. Ki values were deter-
mined from at least three independent experiments.
In a previous in vitro binding screen of 64 functional
receptor/enzyme proteins, MFZ 10-7 bound to two off-
target binding sites at a 10 μM concentration: the
prostaglandin thromboxane A2 receptor (TXA2) and
the peripheral monoamine oxidase-B enzyme (MAO-B;
Keck et al. 2012). To assess the likelihood of these sites
affecting the results of behavioral experiments, the
binding affinities of MFZ 10-7, MTEP and fenobam at
these sites were also determined [National Institute on
Drug Abuse (NIDA) Contract N01DA-8-8877—Caliper
LifeSciences].
Experiment 3: Cocaine self-administration
Animals
Male Long-Evans rats (250–300 g; Charles River Labora-
tories, Raleigh, NC, USA) were used for all experiments.
They were individually housed in a climate-controlled
room on a reverse light–dark cycle (lights on at 1900
hours, lights off at 0700 hours) with ad libitum access to
food and water. All experimental procedures were con-
ducted in accordance with the Guide for the Care and
Use of Laboratory Animals (US National Academy of
Sciences), andwere approved by the Animal Care and Use
Committee of the National Institute on Drug Abuse. The
animal facility was fully accredited by the Association
for Assessment and Accreditation of Laboratory Animal
Care International.
Surgery
Intravenous (i.v.) catheterization of the right external
jugular vein was performed under sodium pentobarbital
(60 mg/kg, i.p.) anesthesia, utilizing standard aseptic
surgical techniques as we reported previously (Xi et al.
2010, 2013). To help prevent clogging, the catheters
were flushed daily with a gentamicin–heparin–saline
solution (0.1 mg/ml gentamicin, 30 IU/ml heparin; ICN
Biochemicals, Cleveland, OH, USA).
Apparatus
Self-administration chambers from MED Associates Inc.
(Saint Albans, VT, USA) were the same as used previously
(Xi et al. 2010, 2013).
Multiple-dose cocaine self-administration
To determine whether MFZ 10-7 or MTEP attenuates
cocaine’s rewarding efficacy, we observed the effects
of both compounds on the cocaine dose–response
self-administration curve. This is based upon the well-
accepted view that a leftward or upward shift of a dose–
response curve reflects an increase in pharmacological
action, and vice versa (Hiranita et al. 2009). After recov-
ery from surgery, each rat was placed into a test chamber
and allowed to lever-press for i.v. cocaine (1 mg/kg/infu-
sion) on a fixed ratio 1 (FR1) reinforcement schedule.
Each cocaine infusion delivered a volume of 0.08 ml/
infusion over 4.65 seconds and was paired with the
simultaneous presentation of a stimulus light and tone
(each lasting 4.65 seconds). Each session lasted 3 hours.
FR1 reinforcement was used for 5 days to establish
stable self-administration. Subjects were then allowed
to continue cocaine self-administration (0.5 mg/kg/
infusion) under FR2 reinforcement. After stable self-
administration was established on the FR2 schedule (less
than 10% variation in total infusions over 3 consecutive
days), animals were switched to multiple-dose cocaine
self-administration maintained by a full range of cocaine
doses (0.03, 0.06, 0.125, 0.25, 0.5, 1.0 mg/kg/infusion)
in a single dose–response session (Hiranita et al. 2009;
Keck et al. 2013). Each dose–response session consisted
of six sequential trials, beginning with a 30-minute
extinction period (0 mg/kg cocaine) followed by six
20-minute components in which different cocaine doses
were delivered. A 20-minute intertrial time-out period
was included between each session to allow for changing
the cocaine dose. Infusion volume, infusion duration and
the presentation of a stimulus light and tone (each
lasting 4.65 seconds) during the infusion remained con-
stant across all trials. Self-administration continued until
stable cocaine-maintained responding was achieved (i.e.
a minimum of 10 mg/kg cocaine intake within a session
and less than 10% variation in total number of cocaine
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infusions for 3 consecutive days). Then, each rat (n = 7)
randomly received either vehicle or one of two doses of
MFZ 10-7 (3, 10 mg/kg, i.p.) or MTEP (3, 10 mg/kg, i.p.)
15 minutes prior to the test session. Animals then
received an additional 2–3 days of self-administration of
cocaine alone until the baseline response rate was rees-
tablished prior to testing the next dose of MTEP or MFZ
10-7. The order of testing for the various doses of drug
or vehicle was counterbalanced.
Single-dose cocaine self-administration
Given that the multiple-dose cocaine self-administration
experiment lasted at least 4 hours per test session, while
the pharmacological action of a test drug may last
shorter than 4 hours, it is likely that a single injection
of a test drug may inhibit self-administration maintained
by initial lower doses of cocaine, but not by subsequent
high doses of cocaine. Therefore, we used two additional
groups of rats (n = 7–11 per group) to study whether a
single injection of MFZ 10-7 or MTEP inhibits cocaine
self-administration maintained by a single high dose
(0.5 mg/kg/injection) of cocaine. The initial cocaine self-
administration procedures were the same as described
above. Each session lasted 3 hours. To avoid cocaine over-
dose during the self-administration period, each animal
was limited to a maximum of 50 cocaine injections per
3-hour session. After stable self-administration was
established on the FR2 schedule (less than 10% variation
in total infusions over 3 consecutive days), the effects of
MFZ 10-7 and MTEP on cocaine self-administration
were assessed. Drugs were administered (i.p.) 15 minutes
prior to testing. After each drug test, animals continued
daily cocaine self-administration until stable self-
administration was reestablished. The order of testing for
various doses of each compound was counterbalanced.
Experiment 4: Sucrose self-administration
The procedures for sucrose self-administration were iden-
tical to the procedures for cocaine self-administration
except for the following: (1) no surgery was performed on
the animals; (2) active lever presses led to delivery of
0.1 ml of 5% sucrose solution into a liquid food tray on
the operant chamber wall along with presentation of a
stimulus light and tone; (3) 3-hour FR1 acquisition ses-
sions were capped at 100 deliveries; and (4) test sessions
were 90 minutes in length and were capped at 100 deliv-
eries. After stable sucrose self-administration was estab-
lished on the FR1 schedule (less than 10% variation in
total deliveries over 3 consecutive days), the effects of
MFZ 10-7 and MTEP on sucrose self-administration were
determined in two separate groups of rats (n = 7 per
group). Drug doses and administration methods were
identical to the cocaine self-administration experiments.
Experiment 5: Sucrose-triggered reinstatement of
sucrose-seeking behavior
Two additional group of rats (n = 15 total) were used to
evaluate the effects of MFZ 10-7 and MTEP on sucrose-
induced reinstatement of sucrose-seeking behavior. After
stable sucrose self-administration was achieved, animals
underwent extinction sessions until sucrose-seeking
behavior was extinguished. To determine whether MFZ
10-7 or MTEP pretreatment inhibits relapse to sucrose-
seeking behavior, extinguished animals were treated
with vehicle, MFZ 10-7 or MTEP prior to reinstatement
triggered by five non-contingent sucrose deliveries
(which were subtracted from the total number of sucrose
reinforcements for data analysis) within the initial 5
minutes of testing. The animals were divided into two
dose groups. Group 1 (n = 10) randomly received either
vehicle or one of two doses of MFZ 10-7 (3, 10 mg/kg,
i.p.). Group 2 (n = 5) randomly received either vehicle or
one of two doses of MTEP (3, 10 mg/kg, i.p.). The order
of testing for the various doses of drug or vehicle was
counterbalanced and there were two intervening extinc-
tion trials between each test. Lever presses during the
reinstatement tests were recorded, but did not lead to
either sucrose delivery or presentation of the conditioned
cue-light and tone.
Experiment 6: Cocaine-primed reinstatement of
cocaine-seeking behavior
After the completion of the single-dose cocaine self-
administration study from Experiment 3, 11 animals
tested with MTEP and 9 animals tested with MFZ 10-7
during cocaine self-administration were used in this
experiment to observe the effects of MTEP or MFZ 10-7
on cocaine-induced reinstatement of drug-seeking
behavior, respectively. This is based on our observation
that the effects of MTEP or MFZ 10-7 on cocaine self-
administration lasted only a few hours (3–4 hours) and
was completely reversible 24 hours after the drug admin-
istration. There is no tolerance or sensitization to the
biological effects observed after MTEP or MFZ 10-7
administration. To further exclude the potential effects
of previous MFZ 10-7 treatment history on the effects
of MFZ 10-7 on cocaine-induced reinstatement of drug-
seeking behavior, we used eight additional animals
without MFZ 10-7 treatment history during the self-
administration phase in the MFZ 10-7 group of rats to
compare the effects of MFZ 10-7 on cocaine-induced
reinstatement of drug-seeking behavior between two
groups of rats with or without MFZ 10-7 treatment
history. Additional cocaine self-administration continued
for at least 3–5 days until stable self-administration was
reestablished. Then, the animals underwent extinction
sessions, during which cocaine was replaced by saline
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and the light and sound cues that previously accompa-
nied cocaine infusions were turned off. After the drug-
seeking behavior was extinguished, defined as ≤ 15 active
lever presses during each 3-hour session for at least 3
consecutive days, the effects of MFZ 10-7 and MTEP on
cocaine-primed reinstatement were determined. On the
reinstatement test day, each group of animals received
vehicle, MFZ 10-7 or MTEP 30 minutes prior to cocaine
priming (10 mg/kg, i.p.). Then, the animals were placed
into the operant chambers that were previously paired
with cocaine self-administration. Reinstatement condi-
tions were identical to those in the extinction sessions, i.e.
active lever presses were recorded without cocaine infu-
sions or accompanying cues for 3 hours. Effects of MFZ
10-7 and MTEP on cocaine-induced reinstatement were
assessed by comparing the mean number of active lever
presses per test session.
Experiment 7: Contextual cue-induced incubation of
cocaine seeking
Two groups of rats (n = 12 each group) were used to
examine the effects of MFZ 10-7 and MTEP, respectively,
on cocaine-associated contextual cue-induced cocaine-
seeking behavior. We used a within-subjects design to
evaluate the effects of the drugs on cocaine-associated
contextual cue-induced cocaine-seeking behavior follow-
ing 3 weeks of withdrawal. This is based upon our recent
finding that cue-induced drug-seeking behavior is rela-
tively stable in this period of withdrawal from cocaine
self-administration (Xi et al. 2013). Initial cocaine self-
administration methods were the same as described
above. Following establishment of stable cocaine self-
administration, animalsunderwent3weeksof drugabsti-
nence in which rats were left undisturbed in the housing
facility. Then, on each subsequent test day, rats were
placed into the same self-administration chambers in
which they had been previously tested, and cocaine-
associated contextual cue-induced cocaine-seeking
behavior (i.e. active lever presses) was assessed under
extinction conditions during which cocaine and cocaine-
associated discrete cues (light and tone)were unavailable,
and lever pressing resulted in no consequences. Each
session lasted 3hours. Each animalwas tested three times
with different drug doses, in a counterbalanced fashion,
with MFZ 10-7 (0, 3, 10 mg/kg, i.p., 15 minutes prior to
testing) orMTEP (0, 1, 10 mg/kg, i.p., 15minutes prior to
testing). The interval between drug tests was 2–3 days.
Experiment 8: Effects of MFZ 10-7 and MTEP on
locomotor behavior
To determine whether the reduction in cocaine-taking
and seeking behavior was due to non-specific locomotor
impairment or sedative effects, we observed the effects of
MFZ 10-7 and MTEP on basal locomotor behavior in two
separate groups of rats (n = 8 each). Before testing, drug-
naïve rats were habituated in a locomotor detection
chamber (AccuScan, Columbus, OH, USA) for 1 hour
each day on 2 consecutive days. On each test day, 1 hour
basal levels of locomotor activity were recorded prior to
drug or vehicle administration; drug-induced changes in
locomotor behavior were recorded for an additional 3
hours. Each animal was tested three times with different
drug doses. The time intervals between testing were 2–3
days. Drug doses and administration methods were iden-
tical to the cocaine self-administration experiments.
Drugs
MFZ 10-7 was synthesized at NIDA-IRP according to a
recently published procedure (Keck et al. 2012). MPEP
was purchased from Tocris Bioscience (Ellisville, MO,
USA). MTEP and fenobam free base were provided by the
Drug Supply Program of NIDA (NIDA DPMCDA;
Bethesda, MD, USA). Cocaine HCl was provided by NIDA
and dissolved in physiological saline. For in vitro tests, all
compounds were dissolved in 30% DMSO and water. For
behavioral tests, MFZ 10-7 was suspended in 1% Tween
80 and water for intraperitoneal (i.p.) administration;
MTEP was dissolved in saline for i.p. administration.
Data analysis
All data are presented as means ± standard error of the
mean and were analyzed by using GraphPad Prism soft-
ware (San Diego, CA, USA). One-way analysis of variance
(ANOVA) was used to determine the significance of the
changes in reward-taking or reward-seeking behavior
after eachmGluR5NAMadministration.Whenever a sig-
nificantmain effect was found, individual group compari-
sons were carried out using pre-planned Bonferroni
t-tests.
RESULTS
MFZ 10-7 is a highly potent and selective
mGluR5 NAM
Figure 1 shows the chemical structures and the in vitro
functional potencies of the mGluR5 NAMs: MPEP, MTEP,
MFZ 10-7 and fenobam. MFZ 10-7 was approximately
13-,46-and188-foldmorepotent (lower IC50) thanMPEP,
MTEP and fenobam, respectively. Table 1 shows the
in vitrobinding affinities of MTEP,MFZ10-7and fenobam.
At mGluR5, MFZ 10-7 had approximately 63- and 330-
fold higher binding affinity (lower Ki) than MTEP and
fenobam, respectively. A recent screen of MFZ 10-7
for binding to 64 functional receptor/enzyme proteins
(Keck et al. 2012; NIDAContract N01DA-8-8877-Caliper
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LifeSciences) identified binding to only two off-target sites
at whichMFZ 10-7 boundwith greater than 10 μMaffin-
ity: MAO-B and TXA2. Further analysis determined the
binding affinities of MTEP, MFZ 10-7 and fenobam at
MAO-BandTXA2 (Table 1).MFZ10-7hadapproximately
1150- and 3000-fold lower affinity forMAO-B andTXA2,
respectively, comparedwithmGluR5 (Table 1).MTEPhad
no detectable affinity for TXA2 and was approximately
300-fold selective for mGluR5 over MAO-B (Table 1).
Fenobam had no detectable affinity for MAO-B and was
approximately 25-fold selective for mGluR5 over TXA2
(Table 1).
MFZ 10-7 and MTEP inhibit cocaine self-administration
Figure 2 illustrates the effects of MFZ 10-7 and MTEP on
dose-dependent cocaine self-administration, demonstrat-
ing that a single injection of MFZ 10-7 (Fig. 2a) or MTEP
(Fig. 2c) dose-dependently shifted the cocaine dose–
response curve downward, suggesting a reduction in
cocaine’s rewarding effects after MFZ 10-7 or MTEP
administration. Two-way repeated-measures ANOVA
revealed a statistically significant treatmentmain effect of
MFZ 10-7 (Fig. 2a; F2,90 = 6.33, P < 0.01), a statistically
significant effect of cocaine dose (F5,90 = 3.48, P < 0.01)
and a significant MFZ 10-7 × cocaine dose interaction
(F10,90 = 4.05, P < 0.001). Individual group comparisons
at each cocaine dose revealed a significant reduction in
the number of cocaine infusions after 3 mg/kg MFZ 10-7
(0.06 mg/kg: t = 2.91, P < 0.05; 0.125 mg/kg: t = 3.26,
P < 0.05) or 10 mg/kg MFZ 10-7 (0.06 mg/kg: t = 4.54,
P < 0.001; 0.125 mg/kg: t = 5.33, P < 0.001; 0.25 mg/
kg: t = 3.00, P < 0.05). Two-way repeated-measures
ANOVA revealed no statistically significant treatment
main effect of MTEP (Fig. 2c; F2,90 = 3.06, P = 0.07), a
statistically significant effect of cocaine dose (F5,90 = 5.35,
P < 0.001) and no significant MTEP × cocaine dose
interaction (F10,90 = 1.68, P = 0.10). Individual group
comparisons at each cocaine dose revealed a significant
reduction in the number of cocaine infusions for two
cocaine doses after 10 mg/kg MTEP (0.06 mg/kg:
t = 3.22, P < 0.05; 0.125 mg/kg: t = 3.05, P < 0.05).
Based upon the data shown in Fig. 2a/c, it appears
that MFZ 10-7 and MTEP more effectively attenuate
cocaine self-administration maintained by initial lower
doses (0.03, 0.06, 0.125, 0.25 mg/kg/infusion) of
cocaine than by subsequent higher doses (0.5, 1.0 mg/
kg/infusion) of cocaine. However, because the experi-
mental drugs were given ∼3 hours prior to 0.5 mg/kg
cocaine self-administration testing, we hypothesized that
the peak pharmacological effect of the drugs may have
been over before high dose (0.5–1.0 mg/kg) of cocaine
self-administration began. To test this hypothesis, we
carried out additional experiments to reassess the effects
of MFZ 10-7 and MTEP on single-dose cocaine self-
administration maintained by 0.5 mg/kg/injection.
Figure 2b/d illustrates that systemic (i.p.) administration
of MFZ 10-7 or MTEP, when given 15 minutes prior to
self-administration testing, produced a significant and
dose-dependent reduction in cocaine self-administration.
One-way repeated measures ANOVA revealed a statisti-
cally significant treatment main effect of MFZ 10-7
(Fig. 2b: F2,6 = 10.19, P < 0.01) or MTEP (Fig. 2d:
F2,18 = 7.23, P < 0.01) on total cocaine infusions.
Figure 1 Chemical structures and in vitro functional potencies (IC50) for MPEP, MTEP, MFZ 10-7 and fenobam. *Reported previously in
Keck et al. (2012)
Table 1 Binding affinities of MTEP, MFZ
10-7 and fenobam at mGluR5, MAO-B,
and TXA2.
Binding target MTEP (Ki μM) MFZ 10-7 (Ki μM) Fenobam (Ki μM)
Rat mGluR5 0.042 ± 0.001* 0.00067 ± 0.00001* 0.221 ± 0.010
Rat peripheral
MAO-B
12.9 ± 1.3 0.77 ± 0.16 > 20
Human TXA2 > 20 2.02 ± 0.85 5.63 ± 1.39
*Reported previously in Keck et al. (2012).
MAO-B, monoamine oxidase-B enzyme; TXA2, thromboxane A2 receptor.
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Individual group comparisons demonstrated that each
drug, at the highest tested doses, significantly decreased
cocaine infusions. This effect lasted for less than 24 hours
as cocaine self-administration behavior returned to basal
levels 24 hours after NAM administration. There were no
significant differences in inactive lever responding across
all treatments.
MFZ 10-7 and MTEP inhibit oral sucrose
self-administration rate, but have no effect
on total sucrose intake
Figure 3 illustrates the effects of MFZ 10-7 and MTEP on
oral sucrose self-administration, illustrating that sys-
temic administration of either one failed to alter the
total number of sucrose deliveries (Fig. 3a: F2,6 = 2.04,
P > 0.05; Fig. 3b: F2,6 = 3.72, P > 0.05). Because a limi-
tation of 100 deliveries was set and the majority of
animals completed the maximal number of deliveries
during the 90-minute testing period, we renormalized the
data to the rate of sucrose deliveries per hour (Fig. 3c,d).
The normalized data show that systemic administra-
tion of MFZ 10-7 (Fig. 3c: F2,6 = 25.25, P < 0.001) or
MTEP (Fig. 3d: F2,6 = 5.96, P < 0.05) significantly and
dose-dependently inhibited the rate of oral sucrose self-
administration. Individual group comparisons revealed a
significant reduction in the rate of sucrose delivery after
10 mg/kg MFZ 10-7 (t = 5.77, P < 0.001) and 10 mg/kg
MTEP (t = 3.35, P < 0.05).Therewere no statistically sig-
nificant variations in inactive lever responding across
treatments.
MFZ 10-7 and MTEP inhibit cocaine-primed
reinstatement of cocaine-seeking behavior
Figure 4 illustrates the total number of active and inac-
tive lever presses observed during the last session of
cocaine self-administration, the last session of extinction,
and the reinstatement test session in the three different
dose groups for MFZ 10-7 (Fig. 4a) or MTEP (Fig. 4b). A
single, non-contingent cocaine priming dose (10 mg/kg,
i.p.) produced robust reinstatement of extinguished
operant responding (i.e. active lever presses) in rats pre-
viously reinforced by i.v. cocaine infusions. Pretreat-
ment with MFZ 10-7 or MTEP produced a significant
reduction in cocaine-induced reinstatement of drug-
seeking behavior. One-way ANOVA revealed a statisti-
cally significant treatment main effect of MFZ 10-7
Figure 2 Effects of MFZ 10-7 and MTEP on cocaine self-administration behavior in rats. a, b: MFZ 10-7 (0, 3 or 10 mg/kg by i.p.)
dose-dependently shifted the cocaine dose–response curve downward and inhibited cocaine self-administration maintained by high dose
(0.5 mg/kg/infusion) of cocaine; c, d: MTEP (0, 1, 10 mg/kg, i.p.) shifted the cocaine dose–response curve downward and inhibited cocaine
self-administration maintained by 0.5 mg/kg/infusion cocaine. 3 mg/kg MFZ 10-7 or MTEP: †P < 0.05 compared with vehicle. 10 mg/kg MFZ
10-7 or MTEP: *P < 0.05, **P < 0.01, ***P < 0.001 compared with vehicle
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(Fig. 4a: F2,16 = 52.08, P < 0.001) or MTEP (Fig. 4b:
F2,10 = 6.69, P < 0.01) on active lever responding. Indi-
vidual group comparisons revealed a significant reduc-
tion in drug-seeking after 3 mg/kg (t = 9.42, P < 0.001)
or 10 mg/kg (t = 8.11, P < 0.001) MFZ 10-7 and after
1 mg/kg (t = 2.87, P < 0.05) or 10 mg/kg (t = 3.89,
P < 0.001) MTEP, when compared with vehicle control
groups. There were no statistically significant differences
in inactive lever responding across treatments.
MTEP, but not MFZ 10-7, inhibits sucrose-primed
reinstatement of sucrose-seeking behavior
Figure 5 illustrates the total number of active and inac-
tive lever presses observed during the last three sessions
of sucrose self-administration, the last three sessions
of extinction training, and the reinstatement test ses-
sion in the three different dose groups for MFZ 10-7
(Fig. 5a) or MTEP (Fig. 5b). Five non-contingent sucrose
deliveries produced robust reinstatement of extinguished
operant responding (i.e. active lever presses) in rats pre-
viously reinforced by oral sucrose self-administration.
Pretreatment with MTEP, but not MFZ 10-7, produced a
significant and dose-dependent reduction in sucrose-
induced reinstatement of sucrose-seeking behavior.
One-way ANOVA revealed no statistically significant
treatment main effect of MFZ 10-7 (Fig. 5a: F2,16 = 2.94,
P > 0.05), but a statistically significant treatment main
effect of MTEP (Fig. 5b: F2,10 = 42.91, P < 0.001) on
active lever responding. Individual group comparisons
revealed no significant reductions in sucrose-seeking
after 3 mg/kg (t = 0.06, P > 0.05) or 10 mg/kg (t = 2.13,
P > 0.05) MFZ 10-7, but significant reductions in
sucrose-seeking after 3 mg/kg (t = 7.75, P < 0.001) or
10 mg/kg (t = 8.27, P < 0.001) MTEP, when compared
with vehicle control group. There were no statistically
significant differences in inactive lever responding across
treatments.
MFZ 10-7 and MTEP inhibit cocaine-associated
cue-induced cocaine-seeking behavior
Following cocaine self-administration, animals were
divided into two groups (n = 12 each) that were used to
evaluate the effects of MFZ 10-7 and MTEP, respectively,
on cocaine-seeking behavior (active lever responses) fol-
lowing 21 days of withdrawal (Fig. 6a,b). One-way
ANOVA revealed statistically significant treatment main
effectsof MFZ10-7 (Fig. 6a:F2,11 = 17.72,P < 0.001)and
MTEP (Fig. 6b: F2,11 = 13.19, P < 0.001) on active lever
presses. Individual group comparisons revealed signifi-
cantly reduced active lever responding after 3 mg/kg
(t = 5.70, P < 0.001) or 10 mg/kg (t = 4.33, P < 0.001)
MFZ 10-7 and 10 mg/kg MTEP (t = 5.13, P < 0.001),
when compared with vehicle control groups. Pretreat-
ment with MFZ 10-7 (F2,11 = 7.48, P < 0.01; 10 mg/kg,
t = 3.24, P < 0.05; 3 mg/kg, t = 3.45, P < 0.01) or MTEP
(F2,11 = 5.38, P < 0.05; 10 mg/kg, t = 2.61, P < 0.05;
Figure 3 Effects of MFZ 10-7 and MTEP
on oral sucrose self-administration. a, b:
Total numbers of oral sucrose deliveries
and inactive lever responses; c, d: Rates of
sucrose self-administration (sucrose deliv-
eries per hour), demonstrating that MFZ
10-7 (a) and MTEP (b) did not alter total
sucrose rewards received or inactive lever
responding but dose-dependently reduced
the rate of sucrose delivery (c, d). *P < 0.05,
***P < 0.001 compared with vehicle
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3 mg/kg, t = 0.42, P > 0.05) also significantly inhibited
inactive lever responding in forced drug-abstinent rats.
MFZ 10-7 and MTEP do not inhibit locomotor activity
Figure 7 shows locomotor behavior data from20minutes
before to 180minutes afterMFZ10-7 (Fig. 7a/b) orMTEP
(Fig. 7c/d) administration, illustrating that neither MTEP
nor MFZ 10-7 significantly altered locomotor behavior as
assessed by either binned locomotor counts per unit time
(10-minute intervals; Fig. 7a/c) or cumulative distance
travelled (Fig. 7b/d). Two-way ANOVA for repeated
measures over time for 3h following MFZ 10-7 adminis-
tration revealed a significant main effect of time (Fig. 7a,
F17,357 = 14.44, P < 0.001; Fig. 7b, F17,357 = 66.02,
P < 0.001), a significant drug treatment effect of MFZ
10-7 only in the binned analysis (Fig. 7a, F2,357 = 3.76,
Figure 4 Effects of MFZ 10-7 and MTEP on cocaine-induced rein-
statement of drug-seeking behavior. Pretreatment with MFZ 10-7
(0, 3 or 10 mg/kg, i.p.) (a) or MTEP (0, 1 or 10 mg/kg, i.p.)
(b) dose-dependently inhibited cocaine-induced reinstatement of
drug-seeking behavior in rats after cocaine-taking and cocaine-
seeking behavior was extinguished. *P < 0.05, ***P < 0.001, com-
pared with vehicle
Figure 5 Effects of MFZ 10-7 and MTEP on sucrose-induced
reinstatement of sucrose-seeking behavior. Pretreatment with MFZ
10-7 (3 or 10 mg/kg, i.p.) did not produce a statistically significant
reduction (a), while pretreatment with MTEP (1 or 10 mg/kg, i.p.)
dose-dependently inhibited sucrose-induced reinstatement of
sucrose-seeking behavior (b). ***P < 0.001, compared with vehicle
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P < 0.05; Fig. 7b, F2,357 = 2.74, P > 0.05), and a signifi-
cant time × MFZ 10-7 interaction (Fig. 7a, F34,357 = 1.99,
P < 0.01; Fig. 7b, F34,357 = 2.57, P < 0.001). However,
individual group comparisons revealed no significant
difference at any tested time-point between vehicle and
either dose of MFZ 10-7. Two-way ANOVA for repeated
measures over time for 3 hours following MTEP adminis-
tration revealed a significant time main effect (Fig. 7c,
F17,357 = 14.67, P < 0.001; Fig. 7d, F17,357 = 30.21, P <
0.001), but no significant MTEP treatment effect and no
significant time × MTEP interaction. Individual group
comparisons revealed a significant difference between
vehicle and 1 mg/kg MTEP only in the first 10 minutes
following drug administration in the binned analysis
(Fig. 7c, t = 4.49, P < 0.001) and no significant differ-
ences in the cumulative analysis.
DISCUSSION
The present study compared the in vitro pharmacological
profile of the novel mGluR5 NAM MFZ 10-7 with the
prototypic NAMs MPEP, MTEP and fenobam. We found
that MFZ 10-7 has a substantially higher in vitro potency
and mGluR5 binding affinity compared with MPEP,
MTEP and fenobam. MFZ 10-7 is also more than 1000-
fold selective for mGluR5 over its only known off-targets,
MAO-B and TXA2, making it the most mGluR5-selective
NAM reported in in vivo models of drug abuse, to our
knowledge.
We then compared the in vivo potency of MFZ 10-7
with MTEP in behavioral models of reward-taking and
reward-seeking behaviors, using cocaine and sucrose as
reinforcers. We found: (1) Systemic administration of
either MFZ 10-7 or MTEP attenuated single-dose cocaine
self-administration (0.5 mg/kg/infusion under FR2 rein-
forcement schedule), cocaine-induced reinstatement of
drug-seeking behavior, and cocaine-associated contex-
tual cue-induced cocaine-seeking behavior. (2) MFZ 10-7
appeared to be more potent than MTEP in shifting the
cocaine dose–response curve downward. (3) Although
MFZ 10-7 andMTEP both significantly lowered the rate of
oral sucrose self-administration, they had no effect on the
total number of sucrose deliveries per daily session. Addi-
tionally, we found that MFZ 10-7 was less effective than
MTEP in attenuating sucrose-induced reinstatement of
sucrose-seeking behavior, suggesting relatively higher
selectivity of MFZ 10-7 in attenuation of cocaine-seeking
over sucrose-seeking behavior. (4) The effects of MFZ
10-7 and MTEP on cocaine- and sucrose-seeking
behavior are unlikely the result for sedation as there was
no effect on locomotor behavior. Taken together, the
present study not only provides additional evidence sup-
porting an important role for mGluR5 in cocaine reward
and addiction but also introduces a new tool for further
in vivo andmechanistic investigations into the pharmaco-
therapeutic potential of mGluR5 NAMs.
Drug addiction is characterized by compulsive drug-
taking and drug-seeking behavior following abstinence
(Gawin & Kleber 1986; Satel, Southwick & Gawin 1991).
Intravenous drug self-administration and reinstatement
of drug-seeking behavior are commonly used animal
models to study a drug’s reinforcing effects and relapse
to drug-seeking behavior (O’Brien & Gardner 2005). In
addition, the animal model of incubation of craving
is used to study contextual cue-induced drug-seeking
behavior in which animals are forcibly withdrawn from
cocaine self-administration without behavioral extinc-
tion of the previously reinforced operant responding for
drug reward (Lu et al. 2004).
In the present study, we used multiple animal models
of drug-taking and drug-seeking behavior to evaluate
the pharmacological action of MFZ 10-7 in rats. We
found that MFZ 10-7 and MTEP significantly inhibited
cocaine-taking and cocaine-seeking behavior in rats,
with MFZ 10-7 more potent than MTEP in attenuating
Figure 6 Effects of MFZ 10-7 and MTEP on contextual cue-
induced cocaine-seeking behavior. Pretreatment with MFZ 10-7
(3 or 10 mg/kg, i.p.) (a) or MTEP (1 or 10 mg/kg, i.p.) (b) dose-
dependently inhibited contextual cue-induced cocaine-seeking
behavior (i.e. extinction responding). ***P < 0.001 compared with
active lever after vehicle; ‡P < 0.05, ‡‡P < 0.01 compared with inactive
lever after vehicle
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multiple-dose cocaine self-administration. Attenuation of
cocaine self-administration and a downward shift in the
cocaine dose–response curve are generally interpreted as
a reduction in cocaine’s rewarding effects. In addition, we
also found that both MFZ 10-7 and MTEP inhibited
cocaine priming-induced reinstatement of drug-seeking
behavior and contextual cue-induced incubation of
cocaine seeking, suggesting that mGluR5 NAMs may be
useful in preventing relapse to drug use after abstinence.
Because the same doses of the drugs failed to signi-
ficantly alter basal levels of locomotion, the reduction in
cocaine-taking and cocaine-seeking behaviors observed
in this study are unlikely due to locomotor impairment
followingMTEP orMFZ 10-7 administration. Overall, our
findings are congruent with prior reports that the
mGluR5 NAMs MPEP or MTEP significantly inhibit
cocaine-taking and cocaine-seeking behavior in both
rodents and non-human primates. They are also con-
gruent with our recent report that oral administra-
tion of fenobam sulfate significantly inhibits cocaine
self-administration, cocaine-induced reinstatement
of cocaine-seeking behavior and cocaine-associated
cue-induced cocaine-seeking behavior (Keck et al. 2013).
We note that MFZ 10-7 displayed much higher (30-fold)
potency for mGluR5 than MTEP in the in vitro functional
assays, but we did not see such a difference in the present
in vivo behavioral assays. This may be related to relatively
poor sensitivity of the presently used behavioral tests to
detect a minor-to-moderate difference in the pharmaco-
logical actions of these drugs, and/or different pharma-
cokinetics, metabolism and/or blood-brain barrier
penetration after systemic administration. Interestingly,
MFZ 10-7 was up to 30-fold more potent than MPEP or
MTEP in mouse models of anxiety (Keck et al. 2012). It is
possible that the anxiolytic, antidepressive, and anti-
aggression effects produced by mGluR5 NAMs (Varty
et al. 2005; Navarro et al. 2006; Koros et al. 2007;
Krystal et al. 2010) could contribute to their therapeutic
benefit.
The neuralmechanisms underlying the antagonism of
cocaine reward by mGluR5 NAMs are not fully under-
stood. Multiple studies suggest that mGluR5 blockade
decreases brain reward functioning as measured by the
intracranial self-stimulation reward paradigm (Kenny
Figure 7 Effects of MFZ 10-7 and MTEP on locomotor activity. Following 1 hour of habituation, one dose of MFZ 10-7 (0, 3, or 10 mg/kg,
i.p.) (a/b) or MTEP (0, 1, or 10 mg/kg, i.p.) (c/d) was given. 1 mg/kg MTEP produced a significant increase in locomotion only during the first
10 minutes immediately following drug administration (c). Neither treatment at any dose significantly altered overall locomotion compared
with vehicle (b, d) locomotion. ***P < 0.01 compared with vehicle
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et al. 2005; Cleva et al. 2012), suggesting that attenuated
cocaine self-administration results from a diminished
rewarding response to cocaine. For cocaine- or cue-
induced reinstatement of cocaine-seeking behavior,
previous studies suggest that re-exposure to cocaine-
associated cues or cocaine-priming injections evoke
glutamate release within the nucleus accumbens (NAc)
and ventral tegmental area (VTA) (McFarland, Lapish &
Kalivas 2003;Wang et al. 2005, 2007;Xi et al. 2006;You
et al. 2007; Miguéns et al. 2008). Glutamate neuro-
transmission in these regions has been established to play
an important role in relapse to drug-seeking behaviors
(Knackstedt & Kalivas 2009; Kalivas & Volkow 2011).
mGluR5 receptors are located primarily on somato-
dendritic domains of neurons within corticolimbic
regions including cerebral cortex, olfactory tubercle,
striatum, NAc and lateral septum (Ferraguti & Shigemoto
2006; Mitrano & Smith 2007; Mitrano, Arnold & Smith
2008). Thus, it is plausible that mGluR5 NAMs reduce
postsynaptic mGluR5 signaling in regions such as the
VTA and NAc, thereby attenuating cocaine- or cue-
induced increases in glutamate transmission, thus reduc-
ing reinstatement of drug-seeking behavior.
In contrast to inhibition of cocaine self-
administration, both MFZ 10-7 and MTEP failed to alter
total sucrose intake, but reduced the rate of sucrose self-
administration. The significance of these changes in
sucrose self-administration is unclear. We note that rats
displayed much higher rates of active lever responses for
sucrose (> 100 deliveries per hour) than for cocaine
(10–20 infusions per hour for 0.5 mg/kg cocaine), and
that the majority of rats completed the maximally
allowed 100 sucrose deliveries within 30–40 minutes.
Thus, it is quite expected that a reduction in rate of
sucrose self-administration failed to cause a reduction in
total sucrose deliveries during the 90-minute test dura-
tion. The simplest interpretation of the present findings is
that acutely administered MFZ 10-7 or MTEP attenuate
sucrose’s rewarding effects, lowering motivation for
sucrose-taking and sucrose-seeking behavior. This is con-
sistent with previous reports that MPEP, MTEP and
fenobam decrease food or sucrose self-administration
and reinstatement behavior in rats and non-human pri-
mates (Paterson & Markou 2005; Platt, Rowlett &
Spealman 2008; Keck et al. 2013; Watterson et al. 2013;
but see Martin-Fardon et al. 2009) and reports that
mGluR5 signaling regulates general appetitive behaviors
(Bradbury et al. 2005). We note, however, that while
MTEP also inhibited sucrose-triggered reinstatement of
sucrose-seeking behavior, MFZ 10-7 did not significantly
alter this behavior. At the doses tested, there appears to be
a therapeutic window within which MFZ 10-7 signifi-
cantly alters cocaine-seeking behavior but not sucrose-
seeking behavior.
As stated earlier, neither MPEP nor MTEP have
translational potential for use in humans because of
significant off-target actions and short half-lives. We
have herein included in vitro comparisons with fenobam,
a selective mGluR5 NAM (Porter et al. 2005; Montana
et al. 2009) that has been previously tested in phase
II clinical trials as a non-benzodiazepine anxiolytic
(Friedmann et al. 1980; Pecknold et al. 1982) and as
a treatment for fragile X syndrome (Berry-Kravis et al.
2009). Fenobam has been reported to attenuate cocaine-
(Keck et al. 2013) and methamphetamine-seeking
behavior in rats (Watterson et al. 2013).
Although MTEP and fenobam have previously been
tested in multiple radioligand and enzyme assays to
evaluate their selectivities for mGluR5 (Cosford et al.
2003; Porter et al. 2005), there is no report of these com-
pounds binding to the two off-target sites—TXA2 and
MAO-B. The very low relative binding affinity that MFZ
10-7 had for these two sites in comparison with mGluR5
casts serious doubt that these off-targets mediate the
present findings. Furthermore, neither fenobam nor
MTEP showed high-affinity binding to TXA2 or MAO-B.
Hence, the only known high-affinity target common to
the three structurally diverse ligands MFZ 10-7, MTEP
and fenobam is mGluR5, and it is highly likely that nega-
tive allostericmodulation of this site drives the behavioral
effects observed in the present study and in other pre-
clinical studies utilizing mGluR5 NAMs to attenuate
behaviors associated with drug abuse.
Finally, we note that the MTEP solutions used in the
present study had a pH ranging between 3 and 4, which
might cause abdominal pain and distress after i.p. injec-
tion, thereby potentially contributing to the reduction in
cocaine-taking and cocaine-seeking behavior observed in
the present study. However, we did not observe any signs
of pain and/or distress in locomotion or body movement
up to 3–4 hours after injection. This could be related to
the small injection volume (1 ml/kg) or the analgesic
effects of MTEP after systemic administration (Zhu et al.
2004; Varty et al. 2005).
In summary, MFZ 10-7 is a novel selective and highly
potent mGluR5 NAM, efficacious in attenuating cocaine-
taking and cocaine-seeking behaviors as assessed in
several animal models of cocaine addiction. These pre-
clinical data suggest that MFZ 10-7 is a new tool that can
be used to determine whether mGluR5 is a viable target
formedication development andwithwhichmechanisms
underlying mGluR5’s role in addiction may be further
elucidated.
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